![]() ![]() ![]() Our website aims to empower investorsīy performing the OMER YTD return calculation (with any dividends reinvested as applicable), and to provide aĬoverage universe of many stocks and ETFs to be able to compare YTD returns. More than just the change in price if that instrument pays a dividend or coupon. and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is Thus, researching Year-To-Date Returns is good practice for investors - whether OMER YTD return or other benchmarks/peers Useful in the context of our country's tax system which taxes gains and income on a calendar year basis. Period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely Arguably, choosing the current calendar year for a measurement (up to the end of prior trading session). OMER earned 0.74 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 6.73. Over the past year the S&P 500 is up 11.80 while OMER is higher by 57.55. Is a measure of the total return for a given investment year-to-date for the current calendar year According to 2 analysts, the average rating for OMER stock is 'Sell.' The 12-month stock price forecast is 2.5, which is a decrease of -14.38 from the latest price. OMER is lower by -0.48 from the previous closing price of 5.49 on volume of 486,660 shares. The YTD Return on the OMER YTD return page and across the coverage universe of our site, Clinical development of narsoplimab is focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. The primary drug candidate in its pipeline of complement-targeted therapeutics is narsoplimab, a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Omeros is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |